Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Trial of Pentostatin, Cyclophosphamide, and Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL)
Brief Summary: This phase II trial studies how well giving ofatumumab together with pentostatin and cyclophosphamide works in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Monoclonal antibodies, such as ofatumumab, can block the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as pentostatin and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ofatumumab together with pentostatin and cyclophosphamide may be a better way to block cancer growth.


Options:
A: Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: rituximab arm; Type: EXPERIMENTAL; Interventions: Biological: Rituximab | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): rituximab arm
B: Arm Label: Phase I, NHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: Phase I, CLL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 400/400 mg - Phase II, iNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 1600/800 mg - Phase II, iNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 400/400 mg - Phase II, aNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 1600/800 mg - Phase II, aNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 1000/1000 mg - Phase II, CLL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: Retreated Participants; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): 1000/1000 mg - Phase II, CLL, 1600/800 mg - Phase II, aNHL, 1600/800 mg - Phase II, iNHL, 400/400 mg - Phase II, aNHL, 400/400 mg - Phase II, iNHL, Phase I, CLL, Phase I, NHL, Retreated Participants
C: Arm Label: Idelalisib+ofatumumab; Type: EXPERIMENTAL; Interventions: Drug: Idelalisib, Drug: Ofatumumab | Arm Label: Ofatumumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ofatumumab | Intervention Type: DRUG; Name: Idelalisib; Assigned to Arm(s): Idelalisib+ofatumumab | Intervention Type: DRUG; Name: Ofatumumab; Assigned to Arm(s): Idelalisib+ofatumumab, Ofatumumab
D: Arm Label: Arm A (PCO, closed to accrual as of 8/23/2011); Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Other: Laboratory Biomarker Analysis, Biological: Ofatumumab, Drug: Pentostatin | Arm Label: Arm B (PCO with ofatumumab consolidation); Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Other: Laboratory Biomarker Analysis, Biological: Ofatumumab, Drug: Pentostatin | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm A (PCO, closed to accrual as of 8/23/2011), Arm B (PCO with ofatumumab consolidation) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (PCO, closed to accrual as of 8/23/2011), Arm B (PCO with ofatumumab consolidation) | Intervention Type: BIOLOGICAL; Name: Ofatumumab; Assigned to Arm(s): Arm A (PCO, closed to accrual as of 8/23/2011), Arm B (PCO with ofatumumab consolidation) | Intervention Type: DRUG; Name: Pentostatin; Assigned to Arm(s): Arm A (PCO, closed to accrual as of 8/23/2011), Arm B (PCO with ofatumumab consolidation)

Answer: D